BETHLEHEM, Pa. -- B. Braun, a leading healthcare products and services company and worldwide leader in regional anesthesia, announced today the availability of the LidoSite Topical System, a method to help reduce needlestick pain associated with procedures such as intravenous cannulation, venipuncture, or laser ablation of superficial skin lesions for patients age five and up. The LidoSite Topical System, comprised of the LidoSite Patch (Lidocaine HCl/Epinephrine Topical Iontophoretic Patch) 10 percent/0.1 percent and the LidoSite Controller, provides pain reduction equivalent to a Lidocaine injection without the needlestick.
Unlike the topical anesthetic creams typically used in today's healthcare settings to address needlestick pain, the LidoSite System delivers numbing medication to the procedure site quickly and effectively after a 10-minute application. Topical anesthetic creams usually take up to an hour for full anesthetic benefit.
"Needlesticks for children can arouse more fear than major surgeries and
other more invasive procedures," according to William T. Zempsky, MD,
associate director of the Pain Relief Program at Connecticut Children's Medical
Center. "The LidoSite Topical System offers these patients several
advantages over other commercially available topical anesthetic systems.
Namely, it provides topical anesthesia in just 10 minutes compared to
topical creams requiring 30 to 60 minutes; and it is simple to use --
anesthetic delivery starts with a single button push compared to older
more cumbersome systems."
"A large, multi-center study recently showed that the LidoSite Topical
System was well accepted by children and adults," Zempsky continues.
"LidoSite proves that lidocaine iontophoresis provides not only faster,
but superior depth of anesthesia compared to commonly used prescription
"Many hospitalized children fear a needle more so than other medical
procedures," said Christopher DiBiase, product director for pain control at B.
Braun Medical Inc. "LidoSite provides the necessary anesthesia while
minimizing the pain and anxiety associated with venipuncture."
The LidoSite Topical System enables medical practitioners to easily comply
with American Pain Society (APS) and the American Academy of Pediatrics
(AAP) guidelines for adequately addressing acute- or short-lived pain.
These guidelines, which apply to the treatment of children and adults,
call for healthcare practitioners to eliminate or reduce pain caused by
medical treatments whenever possible. In fact, the APS and AAP agree that
acute pain experienced with medical procedures can, in most cases, be
substantially reduced and even prevented.
Results from many medical facilities' Press-Gainey Patient Satisfaction
surveys show that discomfort associated with obtaining IV access is an
aspect of patient care that requires improvement.(1) To improve patient
care quality, and maintain Joint Commission on Accreditation of Healthcare
Organizations (JCAHO) accreditation, some facilities have identified
reducing pain associated with IV access as a quality improvement goal. The
LidoSite Topical System presents them with an option for meeting this goal
without the drawbacks inherent in existing systems.
The LidoSite Topical System consists of a single-use, pre-filled LidoSite
Patch, filled with Lidocaine HCl 10 percent and Epinephrine 0.1 percent, and the
LidoSite Controller, an easy-to-use pre-programmed device that activates
the patch. Through a proven process called iontophoresis, the Patch is
activated by a mild current from the Controller to accelerate delivery of
Lidocaine, the anesthetic medication, to the injection site.
Epinephrine contained in the LidoSite Patch helps focus the anesthetic
effect directly under the Patch and extends the duration of the effect for
The LidoSite System was developed by Vyteris, Inc., of Fair Lawn, N.J. and
received FDA clearance in 2004. B. Braun is the exclusive marketing
partner of Vyteris for the LidoSite Topical System.
1. Morrison R., et al.: "Pain and Discomfort Associated with Common
Hospital Procedures and Experiences" , Journal of Pain and Symptom
Management. 15(2): 91-101, 1998.
Source: B. Braun Medical Inc.